CSE:QNTM - Post Discussion
Post by
whytestocks on Mar 05, 2024 6:00pm
FSD Pharma Presents Positive Results on First-In-Human Phase
News; $HUGE FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 ForumTORONTO, ON / ACCESSWIRE / March 5, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma " or the " Company "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for ...
HUGE - FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
Be the first to comment on this post